Aims: To determine the frequency and pattern of Hep Par 1 expression in cervical carcinomas of various histological types and to correlate expression with prognostic parameters. Methods: Twenty nine cervical carcinomas were analysed for tumour type, hepatoid and neuroendocrine differentiation, and vascular invasion. A semiquantitative analysis was performed for Hep Par 1, a fetoprotein, chromogranin, and synaptophysin immunoreactivity. Results: Hep Par 1 expression was seen in seven of the 29 cervical carcinomas (three of seven adenocarcinomas, one of 17 squamous cell carcinomas, one of two adenocarcinomas with adenocarcinoma in situ, one of two adenocarcinomas in situ, and one of one large cell neuroendocrine carcinoma with adenocarcinoma in situ). Normal looking endocervical epithelium was also positive in one case. Cases expressing Hep Par 1, with or without neuroendocrine coexpression, were associated with a higher rate of vascular invasion and a worse prognosis. Three of the five cases expressing neuroendocrine markers also coexpressed Hep Par 1. Conclusions: Hep Par 1 expression in carcinoma of the cervix is not uncommon and is present in a variety of histological types. Expression of this marker appears to be associated with more aggressive biological behaviour and a worse prognosis. The uterine cervix is another site that may express Hep Par 1 and hence the use of this antibody in situations of diagnostic difficulty, especially involving lesions within the liver, have to be coupled with the knowledge of the range of tissues it may stain.
T he monoclonal antibody Hep Par 1 has been used to identify tissues of hepatocytic origin and also those with hepatoid differentiation. [1] [2] [3] [4] [5] [6] [7] Although useful in identifying hepatocyte derived tissues/tumours, subsequent studies have shown that tissues from a wide variety of sites and diverse types of tumours may be positive for this marker. 1 3 8-10 Some of these tumours have ''hepatoid'' histomorphology, exhibiting bile production, a fetoprotein (AFP) expression, and albumin expression. 9 11 These extrahepatic hepatoid tumours, with or without Hep Par 1 staining, have been noted to have an increased incidence of vascular invasion, earlier recurrence, and a worse prognosis. [12] [13] [14] Although the incidence of positive staining of these ''non-hepatocytic'' tissue types has so far been low and the Hep Par 1 staining focal, the cumulative experience with this ''aberrant'' staining has lowered the specificity of this antibody for detecting hepatocyte derived tissues. Most of the reported extrahepatic tumours with Hep Par 1 expression and/or hepatoid morphology have been in endodermally derived organs, such as carcinomas of the gastrointestinal tract 8 9 11-19 and lung. 8 9 20 21 However, hepatoid carcinomas expressing AFP have also been described in the uterine corpus, [22] [23] [24] [25] cervix, 26 and urinary bladder, [27] [28] [29] all mesodermal structures. In addition, Hep Par 1 expression has recently been shown in one case each of carcinoma of the uterine corpus and cervix, 8 and in four cases of adenocarcinoma of the urinary bladder. 27 We have encountered a case of large cell neuroendocrine carcinoma (LCNEC) of the cervix with an adenocarcinoma in situ (AIS) component that expressed Hep Par 1 in the in situ component and AFP and neuroendocrine markers in the invasive areas. 30 ''The cumulative experience with this aberrant staining has lowered the specificity of Hep Par 1 for detecting hepatocyte derived tissues''
In our study, we analysed cervical carcinomas to determine the frequency and pattern of immunohistochemical expression of hepatoid and neuroendocrine differentiation and any correlation with prognosis.
MATERIALS AND METHODS
Hysterectomies for cervical carcinoma, including consultation cases, diagnosed in the department of pathology, National University Hospital, Singapore, were reviewed from January 1997 to December 2002. All available archival material and medical records were retrieved. Ten hysterectomies for uterine leiomyomata/adenomyosis were included as controls.
Formalin fixed, paraffin wax embedded blocks of the tumour and adjacent non-neoplastic cervical tissue, in addition to normal cervical tissue from the controls, were used for immunohistochemical studies. Immunostaining for Hep Par 1 was performed with a monoclonal mouse antihuman hepatocyte antibody (Hepatocyte antibody; clone OCH1E5; Dako, Glostrup, Denmark) using the Dako EnVisionH+method. Dewaxed and rehydrated 4 mm histological sections were heated with Dako target retrieval solution at pH 9.9 for 25 minutes. Endogenous peroxide activity was blocked with 3% hydrogen peroxide for 10 minutes. The sections were then incubated with Hepatocyte antibody diluted 1/500 for one hour. After washing in Tris buffered saline (TBS) solution for 10 minutes, the sections were incubated with horseradish peroxidase labelled polymer antimouse antibody complex for 30 minutes and then The microscopic parameters examined were tumour type, histomorphology, and vascular invasion. The tumours were typed according to the World Health Organisation classification. 31 Hepatoid features included polygonal cells with abundant granular or eosinophilic cytoplasm, trabecular/ solid growth pattern, and bile production. A semiquantitative analysis was performed for Hep Par 1, AFP, chromogranin, and synaptophysin immunoreactivity. The extent (percentage) and the intensity of staining (graded mild, moderate, to strong) were recorded, as were the histological and topographical locations of the positive areas.
RESULTS
There were 29 cervical carcinoma specimens comprising 17 squamous cell carcinomas (SCCs), seven adenocarcinomas (ACs), two ACs with AIS, one LCNEC with AIS, one AIS, and one AIS with cervical intraepithelial neoplasia 3 (CIN3). The age range of the patients was from 34 to 65 years. The tumour size ranged from 0.7 to 4.8 cm in maximum dimension. The disease ranged from stage IA1 to IIIB (American Joint Committee on Cancer staging). 
In situ component
Three of the five AIS lesions showed Hep Par 1 positivity ( fig 6) ; staining was strong but patchy, ranging from 10-80% in extent. It was notable that the incumbent invasive components in two of these cases with AIS (cases 1 and 5) were negative. 
Endocervical epithelium
In case 1, the non-dysplastic looking endocervical glands showed strong Hep Par 1 positivity in addition to the AIS component ( fig 7) . No staining was detected in the normal epithelium in the other 28 cases.
Biological behaviour
Three of the four Hep Par 1 positive invasive carcinomas (cases 2, 6 and 7) showed the presence of extensive intravascular tumour emboli; they appeared to have a worse outcome, irrespective of tumour stage at the time of surgery. 
AFP expression
The LCNEC (case 1) was the only sample that expressed AFP, albeit focal (, 5%) and weak to moderate. Staining was confined to the undifferentiated carcinoma cells and not the Hep Par 1 positive AIS areas. When liver metastases developed four months later, the serum AFP concentration was 4697 mg/litre, with corresponding tissue AFP positivity in the fine needle aspiration material of the liver lesions.
Neuroendocrine marker expression
Three Hep Par 1 positive cases (one each of LCNEC, AC, and AIS) showed the presence of neuroendocrine markers (fig 8) . However, there was no apparent histological or topographical correlation between the immunoreactive cells. Vascular invasion was observed only in the LCNEC.
Twenty two of the 29 cases were negative for Hep Par 1 (table 2); they comprised 16 SCCs, four ACs, one AC with AIS, and one AIS. None had hepatoid histomorphology. Two ACs expressed neuroendocrine markers (cases 8 and 9). Five of 21 patients with invasive lesions (all SCCs) showed vascular invasion, with two of them having adverse outcomes-one developed bone metastases two years after initial surgery, whereas the other developed an abdominal wall recurrence one year after surgery. One patient was lost to follow up and the remaining patients are alive and well.
Control cases
No Hep Par 1 staining was detected in the endocervical glands of the 10 non-cancer related hysterectomies.
DISCUSSION
A large proportion of cervical carcinomas (seven of 29) stained with Hep Par 1. However, only one displayed hepatoid features, although another was a clear cell adenocarcinoma resembling fetal gut, a feature observed in hepatoid gastric carcinomas. 17 As such, in most instances there was no reason to suspect a hepatoid connection, least of all to stain with Hep Par 1. It was also notable that there was staining of AIS lesions and even normal looking endocervical epithelium.
The Hep Par 1 positive invasive carcinomas in our study showed a higher rate of vascular invasion (three of four) compared with their Hep Par 1 negative counterparts (five of 21). In some studies, the incidence of vascular invasion in cervical carcinoma has been reported to be as high as 43% in stage I and II tumours, 33 but more commonly in the range of 20-30%, 33 34 correlating with the data for the Hep Par 1 negative cases (24%). Other studies have also noted the propensity of hepatoid carcinomas for vascular permeation. [12] [13] [14] Hence, hepatoid appearance, clear cell features, and/or vascular invasion might be an indicator to stain for Hep Par 1 and AFP.
The overall rate of neuroendocrine marker expression was five of 29. This contrasts with a recent study of cervical carcinoma with synaptophysin expression in only five of 54 cases. histomorphology or AFP expression, and was independent of tumour stage. The two patients with neuroendocrine expression only (Hep Par 1 negative) were alive and well with no evidence of disease recurrence at two years of follow up. This differs somewhat from the findings of Chavez-Blanco et al, 35 who found that their patients with synaptophysin positive cervical carcinomas all relapsed within six months of follow up. In contrast, the two patients with invasive carcinoma who expressed both Hep Par 1 and neuroendocrine markers in the invasive/in situ components (cases 1 and 5) had adverse outcomes, with one patient dying of the disease 2.5 years after initial surgery and the other developing liver metastases. Thus, the coexpression of Hep Par 1 and neuroendocrine markers may herald rapid progression of disease and a poor prognosis, even worse than Hep Par 1 expression alone.
Hep Par 1 expression by carcinomas of the cervix may have diagnostic relevance in the setting of patients with known cervical carcinoma who subsequently develop liver masses. In such cases, the diagnostic differential would be between a primary hepatocellular carcinoma (HCC) and liver metastasis from the primary cervical tumour ( 
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